Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 184,629,728
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 56,655 M
  • Annual Income, $ 8,774 M
  • 36-Month Beta 0.54
  • Price/Sales 3.41
  • Price/Cash Flow 10.46
  • Price/Book 6.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/18
  • Annual Dividend & Yield 0.89 (3.29%)
  • Most Recent Dividend 0.918 on 03/15/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.3000 +5.59%
on 06/08/18
27.8400 -0.25%
on 05/23/18
-0.3650 (-1.30%)
since 05/22/18
3-Month
26.3000 +5.59%
on 06/08/18
28.9800 -4.18%
on 03/28/18
-0.5700 (-2.01%)
since 03/22/18
52-Week
26.3000 +5.59%
on 06/08/18
32.8200 -15.39%
on 06/28/17
-4.5300 (-14.02%)
since 06/22/17

Most Recent Stories

More News
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA

Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.

AGLE : 10.72 (+2.29%)
MRK : 61.47 (+0.47%)
RHHBY : 27.7700 (+2.51%)
BMY : 55.14 (+2.22%)
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

PTCT : 36.01 (-0.83%)
FMI : 136.70 (+0.22%)
NVO : 46.84 (+0.95%)
RHHBY : 27.7700 (+2.51%)
PFE : 36.51 (+0.58%)
GSK : 40.89 (+0.20%)
BMY : 55.14 (+2.22%)
TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche

Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.

FMI : 136.70 (+0.22%)
MRK : 61.47 (+0.47%)
TSRO : 49.62 (+8.46%)
RHHBY : 27.7700 (+2.51%)
Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?

Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.

FMI : 136.70 (+0.22%)
TSRO : 49.62 (+8.46%)
RHHBY : 27.7700 (+2.51%)
SNY : 40.00 (+2.49%)
Roche to Buy Rest of Foundation Medicine for $2.4 billion

Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

AGLE : 10.72 (+2.29%)
FMI : 136.70 (+0.22%)
ANIP : 68.08 (+0.74%)
RHHBY : 27.7700 (+2.51%)
WeissLaw LLP: Foundation Medicine, Inc. Acquisition May Not Be In The Best Interest of FMI Shareholders

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foundation Medicine, Inc. ("FMI" or the "Company") (NASDAQ: FMI) in connection...

FMI : 136.70 (+0.22%)
RHHBY : 27.7700 (+2.51%)
PTC Therapeutics' Spinal Muscular Atrophy Study Successful

PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

PTCT : 36.01 (-0.83%)
AGLE : 10.72 (+2.29%)
RHHBY : 27.7700 (+2.51%)
BIIB : 296.04 (-0.44%)
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

AGLE : 10.72 (+2.29%)
MRK : 61.47 (+0.47%)
IMGN : 12.15 (+4.02%)
RHHBY : 27.7700 (+2.51%)
University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

INDIANAPOLIS and COLUMBIA, Mo. , June 19, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the result of a collaboration with the University of Missouri School of...

ROG : 115.61 (-1.07%)
RHHBY : 27.7700 (+2.51%)
Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.

MRK : 61.47 (+0.47%)
ABBV : 93.49 (-2.16%)
RHHBY : 27.7700 (+2.51%)
BMY : 55.14 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 27.9833
1st Resistance Point 27.8767
Last Price 27.7700
1st Support Level 27.5867
2nd Support Level 27.4033

See More

52-Week High 32.8200
Fibonacci 61.8% 30.3294
Fibonacci 50% 29.5600
Fibonacci 38.2% 28.7906
Last Price 27.7700
52-Week Low 26.3000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar